<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048500</url>
  </required_header>
  <id_info>
    <org_study_id>NU 16L04</org_study_id>
    <secondary_id>STU00204354</secondary_id>
    <secondary_id>NU 16L04</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>NCI-2017-00060</secondary_id>
    <nct_id>NCT03048500</nct_id>
  </id_info>
  <brief_title>Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>Parallel Proof of Concept Phase 2 Study of Nivolumab and Metformin Combination Treatment in Advanced Non-small Cell Lung Cancer With and Without Prior Treatment With PD-1/PD-L1 Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the benefits of combining nivolumab with metformin in&#xD;
      advanced non-small cell lung cancer with and without prior treatment with immunotherapy. We&#xD;
      will also be looking at the safety of the combination. Nivolumab is currently approved in&#xD;
      certain cancers such as melanoma, lung cancer and kidney cancer. Metformin is approved by the&#xD;
      US Food and Drug Administration (FDA) to treat diabetes. In this study, Metformin is being&#xD;
      used to treat cancer. This use is not approved by the FDA; therefore, in this study, it is&#xD;
      considered experimental. Experimental means the U.S. FDA has not approved the drug for use in&#xD;
      your type of cancer. Nivolumab is an antibody (a human protein that sticks to a part of the&#xD;
      tumor and/or immune cells) designed to allow the body's immune system to work against tumor&#xD;
      cells. It is believed that metformin has immune modifying properties, meaning it can boost&#xD;
      your immune system. As a result, it may help certain cancer treatments, known as&#xD;
      immunotherapy, to work better.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess anti-tumor activity of the combination treatment of metformin hydrochloride&#xD;
      (metformin) with nivolumab in patients with non-small cell lung cancer with and without prior&#xD;
      exposure to PD-1/PD-L1 inhibitors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the efficacy of the combination treatment of metformin with nivolumab according&#xD;
      to depth, duration, and persistence of response, disease control rate (DCR; complete response&#xD;
      [CR], partial response [PR], and stable disease [SD] at 24 weeks), progression-free survival&#xD;
      (PFS), and overall survival (OS) in patients with non-small cell lung cancer with and without&#xD;
      prior exposure to PD-1/PD-L1 inhibitors using Response Evaluation Criteria in Solid Tumors&#xD;
      (RECIST) criteria version (v)1.1.&#xD;
&#xD;
      II. To assess the efficacy of the combination treatment of metformin with nivolumab according&#xD;
      to depth, duration, and persistence of response, objective response rate (ORR), DCR, PFS, and&#xD;
      OS in the above population using immune-related RECIST (irRECIST) criteria.&#xD;
&#xD;
      III. To assess the safety and tolerability profile of the combination treatment of metformin&#xD;
      with nivolumab in the above population using Common Terminology Criteria for Adverse Events&#xD;
      (CTCAE) version 4.03.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the immune-related tumor and blood biomarkers including T cell markers and their&#xD;
      association with treatment response in the above population.&#xD;
&#xD;
      II. To assess the dynamic change in both immune and genomic biomarkers in blood that may&#xD;
      correlate with response to metformin.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive metformin hydrochloride orally (PO) once daily (QD) on days -7 to -1 and&#xD;
      1-28. Patients also receive nivolumab intravenously (IV) over 30 minutes on days 1 and 15 of&#xD;
      courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days&#xD;
      in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days, every 3 months for&#xD;
      1 year, then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Actual">September 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using RECIST 1.1</measure>
    <time_frame>up to a maximum of 24 weeks from start of treatment (Range of cycles that best response was seen was 2-5 cycles of treatment where 1 cycle =28 days)</time_frame>
    <description>Anti-tumor activity will be assessed by ORR (defined as the sum of Complete Responses (CR) and/or Partial Responses (PR)) as measured by CT or MRI scan approximately every 8 weeks and assessed by Response Evaluation Criteria in Solid Tumors, RECIST criteria v1.1 using the patients best response to treatment where:&#xD;
CR=Disappearance of all lesions PR=At least a 30% decrease in the sum of the diameters of the target lesions, taking as reference the baseline sum diameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depth of Response</measure>
    <time_frame>24 weeks from start of treatment</time_frame>
    <description>Depth of response (stable disease or partial response) defined as the change in the sum of the largest tumor diameters per RECIST v1.1 and irRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Duration of response will be evaluated using RECIST v1.1 and irRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Persistence of response will be assessed using RECIST v1.1 and irRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>24 weeks from start of treatment</time_frame>
    <description>DCR will be evaluated using RECIST v1.1 and irRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>At 1 year than at 2 years</time_frame>
    <description>PFS will be assessed using RECIST v1.1 and irRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At 1 year than at 2 years</time_frame>
    <description>OS will be assessed using RECIST v1.1 and irRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using irRECIST.</measure>
    <time_frame>up to a maximum of 24 weeks from start of treatment (Range of cycles that best response was seen was 2-6 cycles of treatment where 1 cycle =28 days)</time_frame>
    <description>Anti-tumor activity will be assessed by ORR (defined as the sum of Complete Responses (CR) and/or Partial Responses (PR)) as measured by CT or MRI scan approximately every 8 weeks and assessed by irRECIST criteria using the patients best response to treatment where:&#xD;
CR=Disappearance of all lesions PR=At least a 30% decrease in the sum of the diameters of the target lesions, taking as reference the baseline sum diameters&#xD;
But also new measurable lesions are incorporated in the tumor burden, which is used to determine immune-related progressive disease (irPD), immune-related partial response (irPR), and immune-related complete response (irCR). New non-measurable lesions preclude irCR. Under RECST v1.1, there is no confirmation for PD. Under irRECIST, responses and irPDs must be confirmed by consecutive scans at least 4 weeks apart, assuming no clinical deterioration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Assess the safety and tolerability of the combination treatment of metformin with nivolumab by evaluating the number, frequency, and severity of adverse events using CTCAE version 4.03.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Recurrent Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage III Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIIA Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-Small Cell Lung Cancer</condition>
  <condition>Stage IV Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (metformin hydrochloride, nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (metformin hydrochloride, nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (metformin hydrochloride, nivolumab)</arm_group_label>
    <other_name>Cidophage</other_name>
    <other_name>Dimefor</other_name>
    <other_name>Glifage</other_name>
    <other_name>Glucoformin</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage ER</other_name>
    <other_name>Metformin HCl</other_name>
    <other_name>Riomet</other_name>
    <other_name>Siofor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (metformin hydrochloride, nivolumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed, locally advanced or metastatic stage IV&#xD;
             or non-resectable stage III non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Patients may have received any number and type of prior treatment regimens for their&#xD;
             NSCLC (aside from patients in arm A, who cannot have had PD-1/PD-L1 inhibitors)&#xD;
&#xD;
          -  Arm A: patients must be treatment naive to single agent PD-1/PD-L1 inhibitors&#xD;
             including but not limited to durvalumab, pembrolizumab, atezolizumab, nivolumab, and&#xD;
             avelumab&#xD;
&#xD;
               -  Arm B: patients' tumor must be either refractory to or progressed on one of the&#xD;
                  above agents&#xD;
&#xD;
               -  Both cases are defined by initial progressive disease (PD) or PD after CR, PR, or&#xD;
                  SD using RECIST criteria, respectively&#xD;
&#xD;
          -  Patients must have measurable disease according to the standard RECIST version 1.1&#xD;
&#xD;
               -  NOTE: computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to&#xD;
                  assess the measurable disease must have been completed with 28 days prior to the&#xD;
                  study drug initiation&#xD;
&#xD;
          -  Patients need to have adequate kidney, bone marrow, and liver functions =&lt; 14 days of&#xD;
             registration as specified below:&#xD;
&#xD;
          -  Absolute neutrophil &gt;= 1,000/mcL; transfusion and/or growth factor are permitted&#xD;
             within any timeframe&#xD;
&#xD;
          -  Platelets &gt;= 50,000/mcl; transfusion and/or growth factor are permitted within any&#xD;
             timeframe&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 times the institutional upper limit of normal (ULN) (or =&lt; 3&#xD;
             times ULN in case of liver metastasis or Gilbert syndrome)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SPGT])&#xD;
             =&lt; 2.5 X institutional ULN (or =&lt; 5 times ULN in case of liver metastasis)&#xD;
&#xD;
          -  Creatinine =&lt; 1.4 ng/mL for females; =&lt; 1.5 ng/mL for males; patients with creatinine&#xD;
             =&lt; 2.0 ng/mL may still be eligible if in the opinion of the investigator, the benefits&#xD;
             of treatment outweigh the risks&#xD;
&#xD;
          -  Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of =&lt; 2&#xD;
&#xD;
          -  Patients must have the ability to understand and the willingness to sign a written&#xD;
             informed consent prior to registration on study&#xD;
&#xD;
          -  Females of child-bearing potential (FOCBP) and men who are sexually active must agree&#xD;
             to follow instructions for method(s) of contraception for the duration of treatment&#xD;
             and the designated post-treatment period&#xD;
&#xD;
               -  NOTE: a FOCBP is any woman (regardless of sexual orientation, having undergone a&#xD;
                  tubal ligation, or remaining celibate by choice) who meets the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Has not undergone a hysterectomy or bilateral oophorectomy&#xD;
&#xD;
                    -  Has had menses at any time in the preceding 12 consecutive months (and&#xD;
                       therefore has not been naturally postmenopausal for &gt; 12 months)&#xD;
&#xD;
          -  FOCBP must have a negative pregnancy test =&lt; 7 days prior to registration on study&#xD;
&#xD;
          -  Patients with known history of central nervous system (CNS) metastases are eligible if&#xD;
             CNS disease has been radiographically and neurologically stable for at least 6 weeks&#xD;
             prior to study registration and do not require corticosteroids (of any dose) for&#xD;
             symptomatic management&#xD;
&#xD;
               -  NOTE: CNS imaging is only required at baseline for patients with known history of&#xD;
                  CNS metastases&#xD;
&#xD;
          -  Patients must have the ability to swallow oral medications&#xD;
&#xD;
          -  Patients who are known to be EGFR- or ALK-positive must have received prior EGFR- or&#xD;
             ALK-targeted therapy, respectively&#xD;
&#xD;
               -  NOTE: in such cases, documentation of EGFR mutation or ALK translocation status&#xD;
                  should be provided if available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Both arms: patients should not have received metformin within 6 months prior to&#xD;
             registration&#xD;
&#xD;
               -  Arm B: patients who were on metformin while on PD-1/PD-L1 inhibitors are not&#xD;
                  eligible&#xD;
&#xD;
          -  Patients should not have received prior immunotherapies (exception; arm B); they&#xD;
             include but are not limited to interleukin-2 and other immune checkpoint antagonist&#xD;
             targeting CTLA-4, LAG-3, TIM-3, KIR etc. and/or agonists targeting OX40, ICOS, CD137,&#xD;
             etc&#xD;
&#xD;
               -  NOTE: prior cancer vaccine treatments are permitted; for arm B, exposure to&#xD;
                  single agent PD-1/PD-L1 inhibitors are allowed &gt;= 14 days from registration&#xD;
&#xD;
          -  Arm B: patients must not have had prior exposure to combination treatment with&#xD;
             PD-1/PD-L1 inhibitors and another systemic treatment&#xD;
&#xD;
               -  NOTE: radiation therapy and surgery do not count as combination treatment&#xD;
&#xD;
          -  Patients who are intolerant to PD-1/PD-L1 inhibitors and/or metformin are excluded&#xD;
&#xD;
          -  Patients with active autoimmune disease or history of autoimmune disease that might&#xD;
             recur, which may affect vital organ function or require immune suppressive treatment&#xD;
             including chronic prolonged systemic corticosteroids (defined as corticosteroid use of&#xD;
             duration one month or greater), should be excluded; these include but are not limited&#xD;
             to patients with a history of:&#xD;
&#xD;
               -  Immune related neurologic disease&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Autoimmune (demyelinating) neuropathy&#xD;
&#xD;
               -  Guillain-Barre syndrome&#xD;
&#xD;
               -  Myasthenia gravis&#xD;
&#xD;
               -  Systemic autoimmune disease such as systemic lupus erythematosus (SLE)&#xD;
&#xD;
               -  Connective tissue diseases&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Inflammatory bowel disease (IBD)&#xD;
&#xD;
               -  Crohn's&#xD;
&#xD;
               -  Ulcerative colitis&#xD;
&#xD;
               -  Patients with a history of toxic epidermal necrolysis (TEN)&#xD;
&#xD;
               -  Stevens-Johnson syndrome&#xD;
&#xD;
               -  Anti-phospholipid syndrome&#xD;
&#xD;
                    -  NOTE: subjects with vitiligo, type I diabetes mellitus, residual&#xD;
                       hypothyroidism due to autoimmune condition only requiring hormone&#xD;
                       replacement, psoriasis not requiring systemic treatment, or conditions not&#xD;
                       expected to recur in the absence of an external trigger are permitted to&#xD;
                       enroll&#xD;
&#xD;
          -  Patients are ineligible who have any condition requiring systemic treatment with&#xD;
             corticosteroids (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive&#xD;
             medications =&lt; 14 days prior to registration&#xD;
&#xD;
               -  NOTE: inhaled steroids and adrenal replacement steroid doses &gt; 10 mg daily&#xD;
                  prednisone equivalents are permitted in the absence of active autoimmune disease;&#xD;
                  a brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg,&#xD;
                  contrast dye allergy) or for treatment of non-autoimmune conditions (eg,&#xD;
                  delayed-type hypersensitivity reaction caused by a contact allergen) is permitted&#xD;
&#xD;
          -  Patients who have an uncontrolled intercurrent illness including, but not limited to&#xD;
             any of the following, are not eligible:&#xD;
&#xD;
               -  Uncontrolled hypertension - blood pressure &gt;= 150/90 mmHg despite medical therapy&#xD;
&#xD;
               -  Ongoing or active infection requiring systemic treatment&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
               -  Any other illness or condition that the treating investigator feels would&#xD;
                  interfere with study compliance or would compromise the patient's safety or study&#xD;
                  endpoints&#xD;
&#xD;
          -  Patients must not have had another primary malignancy within 2 years prior to starting&#xD;
             study treatment with the exception of adequately treated basal cell carcinoma,&#xD;
             squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of&#xD;
             the uterine cervix, or any local cancers that are deemed to be cured from&#xD;
             investigator's point of view&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents =&lt; 14 days from&#xD;
             registration&#xD;
&#xD;
          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)&#xD;
             or known acquired immunodeficiency syndrome (AIDS) are excluded&#xD;
&#xD;
          -  Patients who have any positive test for hepatitis B or hepatitis C virus indicating&#xD;
             acute or chronic infection are excluded&#xD;
&#xD;
          -  Patients with known diabetes whose glucose control or general health condition may be&#xD;
             adversely affected by the use of metformin as per the study protocol as deemed by&#xD;
             either the study investigator or endocrinologist are excluded&#xD;
&#xD;
          -  Patients must not have any of the following contraindications to metformin:&#xD;
&#xD;
               -  Hypersensitivity to metformin or any component of the formulation&#xD;
&#xD;
               -  Kidney dysfunction or abnormal creatinine (Cr &lt; 2 ng/mL) from any cause&#xD;
&#xD;
               -  Acute or metabolic acidosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young K. Chae, MD, MPH, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University- Lake Forest Hospital</name>
      <address>
        <city>Lake Forest</city>
        <state>Illinois</state>
        <zip>60045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <results_first_submitted>July 27, 2020</results_first_submitted>
  <results_first_submitted_qc>September 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>September 20, 2020</last_update_submitted>
  <last_update_submitted_qc>September 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Young Kwang Chae</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03048500/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient started treatment July 12, 2017. The study was designed to enroll patients with/without prior PD-1/PD-L1 inhibitor treatment. The study closed enrollment to patients without prior treatment with PD-1/PD-L1 inhibitor April 30, 2018. The study was suspended for IA and subsequently closed to further enrollment August 13, 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Metformin Hydrochloride, Nivolumab)</title>
          <description>Induction: Patients receive treatment with metformin monotherapy PO QD on Day -7 to -1.&#xD;
Main treatment starting Day 1 of Cycle 1: Patients receive metformin PO QD (Days 1-28 of a 28 days cycle) and nivolumab IV every 14 days (on Days 1 and 15 of a 28 day cycle) for the first 4 cycles and then every 28 days, starting Cycle 5 (Day 1 of a 28 day cycle).&#xD;
28 day cycles continue in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Metformin Hydrochloride: Given PO&#xD;
Nivolumab: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>2 Cycles of Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attempted 1st Cycle</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attempted 2nd Cycle</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Reached 1st Response/Continued Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Assessed for First Response</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Went on to Cycle 3 and Beyond</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician decision, Patient PS declining</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up for 3 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">1 patient died whilst on study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Currently in Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Metformin Hydrochloride, Nivolumab)</title>
          <description>Induction: Patients receive treatment with metformin monotherapy PO QD on Day -7 to -1.&#xD;
Main treatment starting Day 1 of Cycle 1: Patients receive metformin PO QD (Days 1-28 of a 28 days cycle) and nivolumab IV every 14 days (on Days 1 and 15 of a 28 day cycle) for the first 4 cycles and then every 28 days, starting Cycle 5 (Day 1 of a 28 day cycle).&#xD;
28 day cycles continue in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Metformin Hydrochloride: Given PO&#xD;
Nivolumab: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using RECIST 1.1</title>
        <description>Anti-tumor activity will be assessed by ORR (defined as the sum of Complete Responses (CR) and/or Partial Responses (PR)) as measured by CT or MRI scan approximately every 8 weeks and assessed by Response Evaluation Criteria in Solid Tumors, RECIST criteria v1.1 using the patients best response to treatment where:&#xD;
CR=Disappearance of all lesions PR=At least a 30% decrease in the sum of the diameters of the target lesions, taking as reference the baseline sum diameters</description>
        <time_frame>up to a maximum of 24 weeks from start of treatment (Range of cycles that best response was seen was 2-5 cycles of treatment where 1 cycle =28 days)</time_frame>
        <population>All patients who received treatment are considered evaluable (even those who did not complete CT scans for RECIST measurement) except those removed from the study for adverse drug reactions.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Metformin Hydrochloride, Nivolumab)</title>
            <description>Induction: Patients receive treatment with metformin monotherapy PO QD on Day -7 to -1.&#xD;
Main treatment starting Day 1 of Cycle 1: Patients receive metformin PO QD (Days 1-28 of a 28 days cycle) and nivolumab IV every 14 days (on Days 1 and 15 of a 28 day cycle) for the first 4 cycles and then every 28 days, starting Cycle 5 (Day 1 of a 28 day cycle).&#xD;
28 day cycles continue in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Metformin Hydrochloride: Given PO&#xD;
Nivolumab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using RECIST 1.1</title>
          <description>Anti-tumor activity will be assessed by ORR (defined as the sum of Complete Responses (CR) and/or Partial Responses (PR)) as measured by CT or MRI scan approximately every 8 weeks and assessed by Response Evaluation Criteria in Solid Tumors, RECIST criteria v1.1 using the patients best response to treatment where:&#xD;
CR=Disappearance of all lesions PR=At least a 30% decrease in the sum of the diameters of the target lesions, taking as reference the baseline sum diameters</description>
          <population>All patients who received treatment are considered evaluable (even those who did not complete CT scans for RECIST measurement) except those removed from the study for adverse drug reactions.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depth of Response</title>
        <description>Depth of response (stable disease or partial response) defined as the change in the sum of the largest tumor diameters per RECIST v1.1 and irRECIST criteria.</description>
        <time_frame>24 weeks from start of treatment</time_frame>
        <posting_date>02/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response will be evaluated using RECIST v1.1 and irRECIST criteria.</description>
        <time_frame>Up to 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Response</title>
        <description>Persistence of response will be assessed using RECIST v1.1 and irRECIST criteria.</description>
        <time_frame>Up to 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>DCR will be evaluated using RECIST v1.1 and irRECIST criteria.</description>
        <time_frame>24 weeks from start of treatment</time_frame>
        <posting_date>02/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS will be assessed using RECIST v1.1 and irRECIST criteria.</description>
        <time_frame>At 1 year than at 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS will be assessed using RECIST v1.1 and irRECIST criteria.</description>
        <time_frame>At 1 year than at 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using irRECIST.</title>
        <description>Anti-tumor activity will be assessed by ORR (defined as the sum of Complete Responses (CR) and/or Partial Responses (PR)) as measured by CT or MRI scan approximately every 8 weeks and assessed by irRECIST criteria using the patients best response to treatment where:&#xD;
CR=Disappearance of all lesions PR=At least a 30% decrease in the sum of the diameters of the target lesions, taking as reference the baseline sum diameters&#xD;
But also new measurable lesions are incorporated in the tumor burden, which is used to determine immune-related progressive disease (irPD), immune-related partial response (irPR), and immune-related complete response (irCR). New non-measurable lesions preclude irCR. Under RECST v1.1, there is no confirmation for PD. Under irRECIST, responses and irPDs must be confirmed by consecutive scans at least 4 weeks apart, assuming no clinical deterioration.</description>
        <time_frame>up to a maximum of 24 weeks from start of treatment (Range of cycles that best response was seen was 2-6 cycles of treatment where 1 cycle =28 days)</time_frame>
        <population>All patients who received treatment are considered evaluable (even those who did not complete CT scans for RECIST measurement) except those removed from the study for adverse drug reactions.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Metformin Hydrochloride, Nivolumab)</title>
            <description>Induction: Patients receive treatment with metformin monotherapy PO QD on Day -7 to -1.&#xD;
Main treatment starting Day 1 of Cycle 1: Patients receive metformin PO QD (Days 1-28 of a 28 days cycle) and nivolumab IV every 14 days (on Days 1 and 15 of a 28 day cycle) for the first 4 cycles and then every 28 days, starting Cycle 5 (Day 1 of a 28 day cycle).&#xD;
28 day cycles continue in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Metformin Hydrochloride: Given PO&#xD;
Nivolumab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using irRECIST.</title>
          <description>Anti-tumor activity will be assessed by ORR (defined as the sum of Complete Responses (CR) and/or Partial Responses (PR)) as measured by CT or MRI scan approximately every 8 weeks and assessed by irRECIST criteria using the patients best response to treatment where:&#xD;
CR=Disappearance of all lesions PR=At least a 30% decrease in the sum of the diameters of the target lesions, taking as reference the baseline sum diameters&#xD;
But also new measurable lesions are incorporated in the tumor burden, which is used to determine immune-related progressive disease (irPD), immune-related partial response (irPR), and immune-related complete response (irCR). New non-measurable lesions preclude irCR. Under RECST v1.1, there is no confirmation for PD. Under irRECIST, responses and irPDs must be confirmed by consecutive scans at least 4 weeks apart, assuming no clinical deterioration.</description>
          <population>All patients who received treatment are considered evaluable (even those who did not complete CT scans for RECIST measurement) except those removed from the study for adverse drug reactions.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Assess the safety and tolerability of the combination treatment of metformin with nivolumab by evaluating the number, frequency, and severity of adverse events using CTCAE version 4.03.</description>
        <time_frame>Up to 3 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from Day -7 of Induction with Metformin until 30 days post the last dose of treatment (or at time of initiation of new treatment) for a maximum of 14 cycles for any patient (where 1 cycle = 28 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Metformin Hydrochloride, Nivolumab)</title>
          <description>Induction: Patients receive treatment with metformin monotherapy PO QD on Day -7 to -1.&#xD;
Main treatment starting Day 1 of Cycle 1: Patients receive metformin PO QD (Days 1-28 of a 28 days cycle) and nivolumab IV every 14 days (on Days 1 and 15 of a 28 day cycle) for the first 4 cycles and then every 28 days, starting Cycle 5 (Day 1 of a 28 day cycle).&#xD;
28 day cycles continue in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Metformin Hydrochloride: Given PO&#xD;
Nivolumab: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>Patient reported to also have spesis at the same time as the event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cardiac arrest and subsequent death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Non-small Cell Lung Cancer</sub_title>
                <description>This resulted in death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hemoptysis and acute chronic obstructive pulmonary disease exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Young Chae, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-1301</phone>
      <email>young.chae@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

